Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase I...

Hong Kong, 28 July, 2016- Sihuan Pharmaceutical Holdings Group Ltd. announced that Imigliptin Dihydrochloride received the approval for Phase II/III clinical trials from China Food and Drug Administra...

Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase II/III Clinical Trials
2018-04-20
RESIGNATION AND APPOINTMENT OF DIRECTORS

The board (the “Board”) of directors (the “Directors”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”, together with its subsidiaries, the “Group”) announces that with effect from...

2017-12-14
RESIGNATION AND APPOINTMENT OF DIRECTORS AND CHANGES IN COMPOSITION OF BOARD COMMITTEES

Mr. Meng Xianhui has resigned as an executive Director and ceased to be the chairman of the risk management committee of the Company in order to devote more time to other business commitments and eng...

2017-09-06
SIHUAN PHARMACEUTICAL INVESTS IN PHARMADAX (FOSHAN) CO., LTD.

Hainan Sihuan Pharmaceutical, a wholly-owned subsidiary of the SIHUAN Pharmaceutical, recently entered into agreements (the “Agreements”) with, among others, PharmaDax Inc. (“PharmaDax”). Accordin...

2017-09-01
Sihuan Pharmaceutical Announces 2017 Interim Results

Sihuan Pharmaceutical Announces 2017 Interim Results, Focused in Low-End Markets and Strengthened Product Brand Building, Major Products and Products at Growth Stage Achieved Satisfying Increase, Prof...

2017-08-30
Sihuan Pharmacentical was granted final decision in favour of the Group on the patent infringement claim related to the

The board of directors (the “Board”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company” or “Sihuan Pharmaceutical”, together with its subsidiaries, collectively the “Group”) announces...

Total 13 Pages  First page  Page up  Page down  Last page

Select

  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012